Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Poniard appoints Gary Lyons to board

This article was originally published in Scrip

Executive Summary

Gary Lyons has joined the board of directors at Poniard Pharmaceuticals (US), a biopharmaceutical company focused on oncology therapies. His appointment brings the number of directors on the board to 10. Mr Lyons has been a consultant to Poniard since April. He has served as a director at Neurocrine Biosciences since February 1993, and held various executive positions with the company, including president and CEO, from February 1993 until January 2008.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC003214

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel